Go Pro
→ This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly (From Investors Alley) (Ad)tc pixel Free AZN Stock Alerts

AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca logo
£117.41 -17.51 (-0.15%)
As of 09/11/2026 12:15 PM Eastern
Compare

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings
Sell
1
Hold
0
Buy
6

Based on 7 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a sell rating, and 6 have given a buy rating for AZN.

Consensus Price Target

£151.14
According to the 7 analysts' twelve-month price targets for AstraZeneca, the average price target is £151.14. The highest price target for AZN is £178, while the lowest price target for AZN is £115. The average price target represents a forecasted upside of 28.74% from the current price of £117.40.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Analyst Ratings Over Time

TypeCurrent Forecast
9/12/25 to 9/12/26		1 Month Ago
8/13/25 to 8/13/26		3 Months Ago
6/14/25 to 6/14/26		1 Year Ago
9/12/24 to 9/12/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target£151.14£152.17£153.33£131.75
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaHealthcare Companies
Consensus Rating Score
2.71
2.30
Consensus RatingModerate BuyHold
News Sentiment Rating
Neutral News

See Recent AZN News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
9/9/2026
Jefferies Financial Group Inc. logo
Jefferies Financial Group
3 of 5 stars
 Reiterated RatingBuy£175+47.95%
9/8/2026
Royal Bank Of Canada logo
Royal Bank Of Canada
3 of 5 stars
 Reiterated RatingOutperform£145+22.59%
9/3/2026
Berenberg Bank logo
Berenberg Bank
2 of 5 stars
 Reiterated RatingBuy£160+32.61%
9/2/2026
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingSell£115-3.72%
7/28/2026
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy£175 ➝ £178+39.50%
1/16/2026
Shore Capital Group Ltd logo
Shore Capital Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
1/15/2026
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:38 PM ET.


Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 11, 2026. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

  • Recent positive Phase III trial data for tozorakimab in COPD, reported in September 2026, demonstrates the company's ability to deliver on its pipeline commitments in the Respiratory & Immunology therapy area, potentially driving future revenue growth.
  • The approval of Etcamah in the U.S. for first-line advanced HR-positive breast cancer in September 2026 expands AstraZeneca PLC's oncology portfolio, a key growth driver where the company reported double-digit growth in H1 2026.
  • Strong H1 2026 financial results, with core operating profit and core EPS rising 11% and total revenue up 6%, indicate solid operational momentum and effective cost management, supporting the current stock price of $11740.50.
  • A consensus rating of Moderate Buy with a price target of 15216.7, as of September 2026, suggests analysts see significant upside potential from the current market valuation, reflecting confidence in the company's long-term strategy.
  • The strategic acquisition of Zegfrovy for up to $1.5 billion in August 2026 strengthens AstraZeneca PLC's lung cancer pipeline, adding a targeted therapy to one of the industry's largest oncology portfolios and supporting its $80 billion revenue goal.

AstraZeneca
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

  • An unexpected failure in a breast cancer trial, reported in September 2026, has caused stock price volatility and raised concerns about the reliability of the company's pipeline, as noted by Jim Cramer who expressed nervousness about missed trials.
  • Deutsche Bank Aktiengesellschaft reaffirmed a "Sell" rating with a price target of £115 in September 2026, indicating that some analysts believe the stock is overvalued or that the company faces significant headwinds in its growth trajectory.
  • The stock price has declined from its 52-week high of $15732.00 to the current $11740.50, reflecting a significant drop in market value over the past year and suggesting potential investor skepticism about future performance.
  • Jim Cramer's public comment in September 2026 that he is "not going to put his money on AstraZeneca" due to missed trials and concerns about COPD, highlights a lack of confidence from a prominent market figure, which could influence broader investor sentiment.
  • The company's reliance on a few key therapy areas, such as Oncology and Respiratory, creates concentration risk, as seen in the stock's reaction to the breast cancer trial failure, making it vulnerable to setbacks in specific product lines.

AZN Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is £151.14, with a high forecast of £178 and a low forecast of £115.

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AZN shares.

According to analysts, AstraZeneca's stock has a predicted upside of 28.74% based on their 12-month stock forecasts.

Over the previous 90 days, AstraZeneca's stock had 1 downgrade by analysts.

AstraZeneca has been rated by research analysts at Berenberg Bank, Citigroup, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, and Royal Bank Of Canada in the past 90 days.

Analysts like AstraZeneca more than other "healthcare" companies. The consensus rating for AstraZeneca is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how AZN compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AstraZeneca Recommendations


MarketBeat monitors more than a dozen sources for AstraZeneca analyst ratings, with the most recent rating issued on 9/9/2026.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
17 Nobel Prize winners… one startling warning
On July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...
Porter & Company | Sponsoredtc pixel
your job is on the list
The CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...
Behind the Markets | Sponsoredtc pixel
I called NVDA at $6 - Here's what’s next…
Matt McCall called NVDA at 6 dollars - it's since climbed more than 3,100 percent. He's identified 51 stocks t...
Monument Traders Alliance | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel